Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research

Hair loss, or alopecia, affects millions worldwide. Androgenetic alopecia, also known as male or female pattern baldness, is the most common form. Despite the scale of this condition, approved treatment options have remained largely restricted to minoxidil and finasteride. In recent years, Kintor Pharmaceutical, a Chinese biopharmaceutical company, has attracted international attention with a topical candidate: KX-826, also called pyrilutamide. KX-826 is an investigational drug. It is not approved as a medicine in any country, it cannot be prescribed, and its long-term safety is unknown. The profile below is worth examining critically, both for what has been reported and for what remains unanswered.

What is KX-826 and How Does It Work?

KX-826 is described as a topical androgen receptor antagonist. Its intended purpose is to block the interaction between dihydrotestosterone (DHT) and androgen receptors in scalp hair follicles. In androgenetic alopecia, hair follicles gradually undergo miniaturization, which reduces their size and the thickness of the hair they produce. Over time this results in visibly thinning hair. DHT is central to that process, and by competing for receptor binding sites KX-826 is designed to interrupt it. Because KX-826 is applied to the scalp, the intended effect is local rather than systemic, which is what would set it apart from oral antiandrogens that act on hormone signalling throughout the body. Whether that separation holds in practice is a question the published data has not yet settled.

Clinical Research: What Has Been Studied So Far?

The first publicly available data came from Kintor's Phase II trial in China (2022): a randomized, double-blind, placebo-controlled study over 24 weeks in men with androgenetic alopecia, testing topical pyrilutamide at 0.25% once daily, 0.5% once daily and 0.5% twice daily. The primary measure was the change in non-vellus (terminal) hair count within a defined scalp area. Kintor reported that participants using KX-826 showed statistically significant improvements compared with placebo. These results are company-disclosed, and peer-reviewed publication of the full dataset remains limited.

A subsequent Phase II trial in the United States (NCT05218642, started 2022) enrolled 123 men over 24 weeks, with several dose groups, including 0.5% twice daily, and a placebo group. In the company's announcement, men using 0.5% twice daily had about 10 more hairs per cm² than at the start of the trial. The company did not report a statistically significant difference from placebo. Once again these findings have been released through investor and corporate channels rather than independent medical journals, which makes independent appraisal impossible for now.

Kintor's first Phase III trial in China (NCT06126965) enrolled 740 men and tested 0.5% twice daily against placebo. In its November 2023 announcement, the company reported that the difference from placebo in hair count at 24 weeks was not statistically significant. Kintor then started a second, adaptive Phase II/III trial in China testing a 1.0% formulation; its 30 December 2024 announcement reported only that the first patient had been enrolled in the Phase III stage. On 18 March 2026 the company announced that this Phase III stage (666 men, 24 weeks) met its primary endpoint: the 1.0% and 0.5% twice-daily groups gained about 10 more hairs per cm² than the placebo group, and the company reported no drug-related serious adverse events. In March 2025 the company also reported results from a separate open-label, 52-week long-term safety trial with no placebo group. Kintor has said it plans to file for approval in China. All of these are company announcements; none of the Phase III results has been published in a peer-reviewed journal.

A Phase II trial in 160 Chinese women with female pattern hair loss (NCT06409650) started in November 2021. This condition, while sharing a hormonal mechanism, often presents with diffuse thinning rather than localized balding. The company has reported that the trial met its primary endpoint, but the data are not peer-reviewed.

Why Topical Application Matters

The rationale behind KX-826 is avoiding systemic exposure. Oral antiandrogens can produce wide-ranging effects, including altered hormone levels and sexual dysfunction. Topical delivery is intended to reduce these risks by limiting how much drug reaches the bloodstream. Safety reports released so far describe mostly mild adverse effects such as temporary scalp redness or irritation, and the company's March 2026 announcement reported no clinically significant difference in adverse events between the KX-826 and placebo groups. Until the pharmacokinetic data are published in full, however, the extent to which systemic absorption is avoided cannot be independently checked.

Critical Considerations and Limitations

Several limitations temper the enthusiasm around KX-826. The placebo-controlled trials reported so far run to 24 weeks, which is short against the lifelong course of androgenetic alopecia; whether any benefit is maintained over years is unknown. The Phase II populations, at roughly 100–120 participants each, are modest, so rare adverse effects may not yet have appeared, although each Phase III trial enrolled several hundred men. There are no head-to-head trials against minoxidil or finasteride, so nobody can say whether KX-826 is better, equivalent or complementary to what already exists. And because most of the data has been disclosed through financial and press communications rather than peer-reviewed journals, the results have not been independently scrutinised.

There is a further practical point. Because KX-826 is not an approved medicine, the only way to obtain it outside a clinical trial is through unregulated research-chemical sellers. Material bought that way is not manufactured to pharmaceutical standards, its actual content and purity are unverified, and nobody is monitoring the person using it. Some community members do this; it is not a supervised or tested route.

What Do We Need to Know Going Forward?

A treatment that targets the androgen receptor locally would be a meaningful addition to a field that has had two mainstays for decades, which is why KX-826 attracts attention. Before it can realistically be placed alongside — or ahead of — current options, longer and larger studies need to be published in independent journals. The open questions are whether results persist beyond 24 weeks, how women respond in a fully reported dataset, and how KX-826 compares directly with existing therapies. Until then it is an experimental compound with mixed, company-reported trial results, not a proven or available treatment.

If you are considering anything for hair loss, talk to a doctor or pharmacist about the approved options first, and about anything you are already taking or applying. KX-826 is not available on prescription and is not something a clinician can currently offer or monitor.

References

Hong Kong Exchanges and Clearing Limited. (2024, October 16). Kintor Pharmaceutical Holdings Limited announcement. Retrieved August 19, 2025, from https://www1.hkexnews.hk/listedco/listconews/sehk/2024/1016/2024101600423.pdf

Hong Kong Exchanges and Clearing Limited. (2025, April 29). Kintor Pharmaceutical Holdings Limited press release. Retrieved August 19, 2025, from https://staticpacific.blob.core.windows.net/press-releases-attachments/3558273/HKEX-EPS_20250429_11653395_0.PDF

Kintor Pharmaceutical. (n.d.). About Kintor. Retrieved August 19, 2025, from https://en.kintor.com.cn/about/1.html

Kintor Pharmaceutical. (2023). Kintor starts Phase II trial for female pattern hair loss. Retrieved August 19, 2025, from https://en.kintor.com.cn/news_details/10.html

Kintor Pharmaceutical. (2023, November 26). Announcement of results of Phase III clinical trial of KX-826 (topline). Reported via MarketScreener: https://www.marketscreener.com/quote/stock/KINTOR-PHARMACEUTICAL-LIM-111325374/news/Kintor-Pharmaceutical-Limited-Announces-Results-of-Phase-III-Clinical-Trial-of-KX-826-Topline-Treatm-45442274/

Kintor Pharmaceutical. (2024, December 30). First subject enrollment in Phase 3 stage of KX-826 1.0% for AGA. https://en.kintor.com.cn/news_details/6.html

Kintor Pharmaceutical. (2026, March 18). Phase III KX-826 tincture 1.0% for AGA reached primary endpoint. https://en.kintor.com.cn/news_details/22.html

ClinicalTrials.gov. Phase III study of KX-826 with adult male patients with AGA. NCT06126965. https://clinicaltrials.gov/study/NCT06126965

ClinicalTrials.gov. To evaluate safety and efficacy of KX-826 in Chinese female subjects with androgenetic alopecia. NCT06409650. https://clinicaltrials.gov/study/NCT06409650

Kintor Pharmaceutical. (2024). Clinical progress of KX-826. Retrieved August 19, 2025, from https://en.kintor.com.cn/news_details/16.html

Kintor Pharmaceutical. (2025). Long-term safety Phase III clinical trial of KX-826 for the treatment of AGA reached primary endpoint. Retrieved from https://en.kintor.com.cn/news_details/9.html

ClinicalTrials.gov. To evaluate efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia. NCT05218642. https://clinicaltrials.gov/study/NCT05218642

Reddit. (2024). AMA with Kintor/Koshine medical scientists. Retrieved August 19, 2025, from https://www.reddit.com/r/Koshine826/comments/1gzktsq/ama_with_kintorkoshine_medical_scientists_the/